​

Evogene (EVGN) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

EVGN Stock Forecast

Evogene (EVGN) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $3.50, with a high of $3.50 and a low of $3.50. This represents a 167.18% increase from the last price of $1.31.

- $1 $2 $3 $4 $5 High: $3.5 Avg: $3.5 Low: $3.5 Last Closed Price: $1.31

EVGN Stock Rating

Evogene stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

EVGN Price Target Upside V Benchmarks

TypeNameUpside
StockEvogene167.18%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.50
Last Closing Price$1.31$1.31$1.31
Upside/Downside--167.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-1---1
Sep, 25-2---2
Aug, 25-2---2
Jul, 25-2---2
Jun, 25-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 22, 2025Ben KlieveLake Street$3.50$1.19194.12%167.18%
Aug 23, 2024Ben KlieveLake Street$12.00$3.54238.98%816.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 22, 2025Lake StreetBuyBuyhold
Mar 07, 2025Alliance Global PartnersBuyBuyhold
Aug 23, 2024Lake StreetBuyBuyhold
Jun 27, 2024Alliance Global PartnersBuyBuyhold
Aug 18, 2023Lake StreetBuyBuyhold
May 02, 2023JMP SecuritiesMarket Outperforminitialise
May 26, 2022RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.75$-0.72$-0.52-----
Avg Forecast$-7.17$-7.60$-5.65$-4.12$-3.11$-2.20$-0.95$-0.10
High Forecast$-7.15$-6.92$-4.85$-3.53$-3.02$-1.89$-0.81$-0.09
Low Forecast$-7.18$-8.28$-6.45$-4.70$-3.20$-2.51$-1.09$-0.11
Surprise %-89.54%-90.53%-90.80%-----

Revenue Forecast

$0 $14M $28M $42M $56M $70M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$930.00K$1.68M$5.64M-----
Avg Forecast$624.00K$1.20M$5.54M$10.53M$14.60M$26.02M$44.89M$63.06M
High Forecast$624.89K$1.28M$6.14M$11.68M$16.20M$28.88M$49.81M$69.97M
Low Forecast$623.11K$1.12M$4.93M$9.37M$13.00M$23.17M$39.97M$56.15M
Surprise %49.04%39.58%1.86%-----

Net Income Forecast

$-35M $-28M $-21M $-14M $-7M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.45M$-29.84M$-23.88M-----
Avg Forecast$-32.74M$-22.35M$-23.88M$-18.80M$-14.21M$-10.05M$-4.34M$-456.86K
High Forecast$-32.68M$-17.88M$-19.10M$-16.12M$-13.80M$-8.62M$-3.72M$-391.77K
Low Forecast$-32.80M$-26.82M$-28.65M$-21.48M$-14.62M$-11.48M$-4.96M$-521.96K
Surprise %-7.01%33.52%------

EVGN Forecast FAQ

Is Evogene stock a buy?

Evogene stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Evogene is a favorable investment for most analysts.

What is Evogene's price target?

Evogene's price target, set by 4 Wall Street analysts, averages $3.5 over the next 12 months. The price target range spans from $3.5 at the low end to $3.5 at the high end, suggesting a potential 167.18% change from the previous closing price of $1.31.

How does Evogene stock forecast compare to its benchmarks?

Evogene's stock forecast shows a 167.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Evogene over the past three months?

  • October 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Evogene’s EPS forecast?

Evogene's average annual EPS forecast for its fiscal year ending in December 2024 is $-4.12, marking a 692.31% increase from the reported $-0.52 in 2023. Estimates for the following years are $-3.11 in 2025, $-2.2 in 2026, $-0.95 in 2027, and $-0.1 in 2028.

What is Evogene’s revenue forecast?

Evogene's average annual revenue forecast for its fiscal year ending in December 2024 is $10.52M, reflecting a 86.61% increase from the reported $5.64M in 2023. The forecast for 2025 is $14.6M, followed by $26.02M for 2026, $44.89M for 2027, and $63.06M for 2028.

What is Evogene’s net income forecast?

Evogene's net income forecast for the fiscal year ending in December 2024 stands at $-18.8M, representing a -21.27% decrease from the reported $-23.879M in 2023. Projections indicate $-14.208M in 2025, $-10.051M in 2026, $-4.34M in 2027, and $-457K in 2028.